Efficacy and safety of dose-escalated alectinib in patients with metastatic ALK-positive NSCLC and CNS relapse on standard dose alectinib

被引：0
|
作者：
Cheung, Justin Matthew
Kang, Jiyoon
Yeap, Beow Y.
Peterson, Jenn
Do, Andrew
Digumarthy, Subba R.
Gainor, Justin F.
Lin, Jessica Jiyeong
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21079
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
    Hiroshi Hashimoto
    Kazuyuki Komori
    Koji Kameda
    Shinichi Taguchi
    Yuichi Ozeki
    Surgical Case Reports, 8
  • [32] Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
    Yu, Hui
    Sun, Si
    Hu, Xingjiang
    Xia, Jinjing
    Wang, Jialei
    Chen, Haiquan
    ONCOTARGETS AND THERAPY, 2019, 12 : 6481 - 6495
  • [33] ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials
    Noe, Johannes
    Lovejoy, Alex
    Ou, Sai-Hong Ignatius
    Yaung, Stephanie J.
    Bordogna, Walter
    Klass, Daniel M.
    Cummings, Craig A.
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (04) : 601 - 608
  • [34] CNS Outcomes in ALK Fusion Positive NSCLC Patients with BM Who Received Alectinib with or without Local Therapy
    Miao, E.
    Lebow, E. S.
    Eichholz, J.
    Flynn, J.
    Zhang, Z.
    Hubbeling, H. G.
    Beal, K.
    Moss, N. S.
    Yu, K.
    Yang, J. T.
    Kelly, D. W.
    Gomez, D. R.
    Rimner, A.
    Drilon, A.
    Imber, B. S.
    Pike, L. R. G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E59 - E60
  • [35] Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC
    Song, Lianxi
    Xu, Qinqin
    Lizaso, Analyn
    Zhang, Yongchang
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 349 - 351
  • [36] Successful salvage surgery followed by second ALK-TKI after alectinib failure in a patient with ALK-positive NSCLC
    Hashimoto, Hiroshi
    Komori, Kazuyuki
    Kameda, Koji
    Taguchi, Shinichi
    Ozeki, Yuichi
    SURGICAL CASE REPORTS, 2022, 8 (01)
  • [37] Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report
    Xia, Guohao
    Huang, Jiayuan
    Ni, Jie
    Song, Meng
    Zhang, Junling
    Hofman, Paul
    Christopoulos, Petros
    Grenda, Anna
    Huang, Mengli
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (03) : 637 - 646
  • [38] Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?
    Urbanska, Edyta Maria
    Sorensen, Jens Benn
    Santoni-Rugiu, Eric
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : 28 - 29
  • [39] Alectinib after Crizotinib Failure in Patients with Advanced ALK-Positive NSCLC: Results from the Spanish Early Access Program
    Bernabe-Caro, R.
    Garcia-Campelo, R.
    Garrido, P.
    Palmero, R.
    Artal, A.
    Bayona, C.
    Rodriguez-Abreu, D.
    Lopez-Brea, M.
    Paredes, A.
    Vicente, D.
    Torres, J. M. Sanchez
    Majem, M.
    Diz, P.
    Gordo, R.
    Coca, M.
    de Castro, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S465 - S466
  • [40] Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer
    Yoshida, Hironori
    Kim, Young Hak
    Ozasa, Hiroaki
    Sakamori, Yuichi
    Tsuji, Takahiro
    Nomizo, Takashi
    Yasuda, Yuto
    Yamamoto, Tomoko
    Ajimizu, Hitomi
    Hirai, Toyohiro
    IN VIVO, 2018, 32 (06): : 1587 - 1590
12345